%0 Journal Article
%T Translating the role of PARP inhibitors in triple-negative breast cancer
%A Mich¨¨le Beniey
%A Saima Hassan
%A Takrima Haque
%J Archive of "Oncoscience".
%D 2019
%R 10.18632/oncoscience.474
%X Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive subtype of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2. Patients with TNBC have a poorer overall survival and tend to progress within three years of diagnosis [1]. The therapeutic management of TNBC is a significant challenge, since patients cannot benefit from antihormonal or HER2-directed therapy, and are commonly offered several types of cytotoxic chemotherapy
%K triple-negative breast cancer
%K PARP inhibitors
%K predictors of response
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382255/